nach oben

HNO

Erschienen in:

31.01.2020 | Leitthema

Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids

verfasst von: S. Ferrone, MD, PhD, T. L. Whiteside, PhD

Erschienen in: HNO | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

This manuscript describes the functional properties of the exosomes released from melanoma cells. It details the characteristics of the tumor antigen chondroitin sulfate proteoglycan 4 (CSPG4), which is used as a marker to separate exosomes released by melanoma cells from exosomes released by nonmalignant cells. The results are discussed in view of the potential role of melanoma cell-derived exosomes in the escape of malignant cells from the host’s immune system.

Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–1355. https://doi.org/10.1126/science.aar4060 CrossRefPubMed

Weiss SA, Wolchok JD, Sznol M (2019) Immunotherapy of melanoma: facts and hopes. Clin Cancer Res 25(17):5191–5201. https://doi.org/10.1158/1078-0432.CCR-18-1550 CrossRefPubMed

Pires da Silva I, Lo S, Quek C, Gonzalez M, Carlino MS, Long GV, Menzies AM (2019) Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD‑1 therapy. Cancer. https://doi.org/10.1002/cncr.32522 CrossRefPubMed

Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T‑cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273CrossRef

Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S (2018) Defective HLA class I antigen processing machinery in cancer. Cancer Immunol Immunother 67(6):999–1009. https://doi.org/10.1007/s00262-018-2131-2 CrossRefPubMed

Munn DH, Mellor AL (2016) IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol 37(3):193–207. https://doi.org/10.1016/j.it.2016.01.002 CrossRefPubMedPubMedCentral

Ohta A (2016) A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol 7:109. https://doi.org/10.3389/fimmu.2016.00109 CrossRefPubMedPubMedCentral

Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8(8):2553–2562PubMed

Whiteside TL (2015) The role of regulatory T cells in cancer immunology. Immunotargets Ther 4:159–171. https://doi.org/10.2147/ITT.S55415 CrossRefPubMedPubMedCentral

10.

Ostrand-Rosenberg S (2018) Myeloid derived-suppressor cells: their role in cancer and obesity. Curr Opin Immunol 51:68–75. https://doi.org/10.1016/j.coi.2018.03.007 CrossRefPubMedPubMedCentral

11.

Wu Y, Chen W, Xu ZP, Gu W (2019) PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol 10:2022. https://doi.org/10.3389/fimmu.2019.02022 CrossRefPubMedPubMedCentral

12.

Damgaci S, Ibrahim-Hashim A, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ (2018) Hypoxia and acidosis: immune suppressors and therapeutic targets. Immunology 154(3):354–362. https://doi.org/10.1111/imm.12917 CrossRefPubMedPubMedCentral

13.

Whiteside TL (2017) Exosomes carrying immunoinhibitory proteins and their role in cancer. Clin Exp Immunol 189(3):259–267. https://doi.org/10.1111/cei.12974 CrossRefPubMedPubMedCentral

14.

Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S (2004) Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24:267–296CrossRef

15.

Campoli M, Ferrone S, Wang X (2010) Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 109:73–121CrossRef

16.

Ruivo CF, Adem B, Silva M, Melo SA (2017) The biology of cancer exosomes: insights and new perspectives. Cancer Res 77(23):6480–6488. https://doi.org/10.1158/0008-5472.CAN-17-0994 CrossRefPubMed

17.

Hessvik NP, Llorente A (2018) Current knowledge on exosome biogenesis and release. Cell Mol Life Sci 75(2):193–208. https://doi.org/10.1007/s00018-017-2595-9 CrossRefPubMed

18.

Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18(6):883–891. https://doi.org/10.1038/nm.2753 CrossRefPubMedPubMedCentral

19.

Whiteside TL (2017) The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. Future Oncol 13(28):2583–2592. https://doi.org/10.2217/fon-2017-0343 CrossRefPubMedPubMedCentral

20.

Mulcahy LA, Pink RC, Carter DR (2014) Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. https://doi.org/10.3402/jev.v3.24641 CrossRefPubMedPubMedCentral

21.

Kurywchak P, Tavormina J, Kalluri R (2018) The emerging roles of exosomes in the modulation of immune responses in cancer. Genome Med 10(1):23. https://doi.org/10.1186/s13073-018-0535-4 CrossRefPubMedPubMedCentral

22.

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD‑1 response. Nature 560(7718):382–386. https://doi.org/10.1038/s41586-018-0392-8 CrossRefPubMedPubMedCentral

23.

Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL (2009) Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 183(6):3720–3730. https://doi.org/10.4049/jimmunol.0900970 CrossRefPubMedPubMedCentral

24.

Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL (2019) Melanoma cell-derived exosomes in plasma of melanoma patients mediate suppression of immune effector cells. Sci Rep 2020 10(10):92. https://doi.org/10.1038/s41598-019-56542-4 CrossRefPubMedPubMedCentral

25.

Hong CS, Funk S, Muller L, Boyiadzis M, Whiteside TL (2016) Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. J Extracell Vesicles 5:29289. https://doi.org/10.3402/jev.v5.29289 CrossRefPubMed

26.

Sharma P, Ludwig S, Muller L, Hong CS, Kirkwood JM, Ferrone S, Whiteside TL (2017) Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. J Extracell Vesicles 7(1):1435138. https://doi.org/10.1080/20013078.2018.1435138 CrossRef

27.

Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, Favole A, Tsuchikawa T, Silver S, Watkins SC, Kageshita T, Ferrone S (2011) Functional characterization of an scFV antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res 71:7410–7422CrossRef

28.

Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ (1990) Expression of the high molecular weight melanoma associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136:1393–1405PubMedPubMedCentral

29.

Maciag PC, Seavy MM, Pan ZK, Ferrone S, Paterson Y (2008) Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 68:8066–8075CrossRef

30.

Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA, Morgan RA (2014) Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J Immunother Cancer 2:25CrossRef

31.

Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, Morgan RA (2013) Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res 19(18):4941–4950. https://doi.org/10.1158/1078-0432.CCR-13-1253 CrossRefPubMedPubMedCentral

32.

Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy J, Brufsky A, Chivukula M, Khoury T, Hsu D, Lyerly H, Clay T, Ferrone S (2010) CSPG4 as a new target for antibody-based immunotherapy of triple negative breast cancer. J Natl Cancer Inst 102:1496–1512CrossRef

33.

Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89:466–470CrossRef

34.

Riccardo F, Iussich S, Maniscalco L, Mayayo SL, Rosa GL, Arigoni M, Maria RD, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F (2014) CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res 20:3753–3762CrossRef

35.

Léger O, Johnson-Léger C, Jackson E, Coles B, Dean C (1994) The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN. Int J Cancer 58(5):700–705CrossRef

36.

Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann MM, Ferrone S, Dotti G (2014) T lymphocytes redirected against the chondroitin sulfate proteoglycan‑4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res 20:962–971CrossRef

Titel: Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids
verfasst von: S. Ferrone, MD, PhD
T. L. Whiteside, PhD
Publikationsdatum: 31.01.2020
Verlag: Springer Medizin
Erschienen in: HNO / Ausgabe 2/2020
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI: https://doi.org/10.1007/s00106-019-00811-1

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

CME: Komplikationen bei Piercings und Tätowierungen im Kopf-Hals-Bereich

Allergoonkologie: was Allergologen und Onkologen voneinander lernen können

Adenosine production in mesenchymal stromal cells in relation to their developmental status

Exosomen: Nanostaub?

„Immunosuppression and Immunotherapy in Cancer“

Immunotherapeutics for head and neck squamous cell carcinoma stem cells

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO